<DOC>
	<DOCNO>NCT00453856</DOCNO>
	<brief_summary>IPTi , strategy whereby infant provide treatment dos antimalarial routine vaccination visit , show significantly reduce malaria anemia two study Tanzania . However result obtain Gabon similar . Many factor likely influence efficacy effectiveness IPTi . It reasonable assume efficacy IPTi influence markedly sensitivity Plasmodium falciparum antimalarial drug ( Sulfadoxine-Pyrimethamine ) use IPTi . In order interpret result individual IPTi trial conduct IPTi Consortium , provide information policy maker regard predict efficacy IPTi , essential obtain information antimalarial drug sensitivity Sulfadoxine-Pyrimethamine IPTi trial conduct . The simple universally accepted measure test antimalarial drug efficacy `` vivo efficacy study , '' follow standardize World Health Organization protocol . A second reason evaluate drug resistance adjunct IPTi trial determine intervention increase carriage and/or spread drug resistant P. falciparum parasite . Thirdly overall effect community level selection resistant genotypes IPTi-recipients unclear .</brief_summary>
	<brief_title>Efficacy Sulfadoxine-Pyrimethamine Treating Malaria Gabonese Children</brief_title>
	<detailed_description>Administration standard single oral dose sulfadoxine-pyrimethamine child age 6-59 month old child Lambaréné enrolment , eligible accord approve protocol . 139 subject enrol treat Sulfadoxine-Pyrimethamine uncomplicated malaria . Thereafter subject follow accord approve protocol The proportion subject Adequate Clinical Parasitological response ( ACPR ) day 28 , Early Treatment Failure ( ETF ) , Late Clinical Failure ( LCF ) Late Parasitological Failure ( LPF ) evaluate . secondly frequency molecular marker Sulfadoxine-Pyrimethamine drug resistance determine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Male female outpatient Aged 6 59 month Body weight 7.5 30 kg uncomplicated falciparum malaria parasitaemia 1,000/µL 200,000/µL Ability tolerate oral therapy Informed consent , oral agreement child appropriate Still IPTi trial and/or still intervention trial Known G6PDdeficiency Presence severe malnutrition Inability drink breastfeed Recent history convulsion , lethargy unconsciousness ; Signs severe complicate Mixed/mono infection include nonP . falciparum specie . Hb &lt; 7g/dl Inability attend stipulate followup visit . History hypersensitivity reaction drug evaluate</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Sulfadoxine</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Resistance</keyword>
	<keyword>Gabon</keyword>
</DOC>